Paul Angulo

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Use of ursodeoxycholic acid in patients with liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 4:37-44. 2002
  2. ncbi NAFLD, obesity, and bariatric surgery
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gastroenterology 130:1848-52. 2006
  3. ncbi Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55095, USA
    J Hepatol 41:943-9. 2004
  4. ncbi Current best treatment for non-alcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 4:611-23. 2003
  5. ncbi Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 53:1716-20. 2008
  6. ncbi Nonalcoholic fatty liver disease and liver transplantation
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:523-34. 2006
  7. ncbi The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:846-54. 2007
  8. ncbi [Cholestatic syndromes]
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine
    Rev Gastroenterol Mex 70:45-51. 2005
  9. ncbi Nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Rev Gastroenterol Mex 70:52-6. 2005
  10. ncbi Obesity and nonalcoholic fatty liver disease
    Paul Angulo
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Nutr Rev 65:S57-63. 2007

Research Grants

  1. Prognosis of Nonalcoholic Fatty Liver Disease
    Paul Angulo; Fiscal Year: 2009

Detail Information

Publications74

  1. ncbi Use of ursodeoxycholic acid in patients with liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 4:37-44. 2002
    ..However, unlike the effects of UDCA in primary biliary cirrhosis, the long-term effects of UDCA in disease progression and survival in these other conditions remain to be established...
  2. ncbi NAFLD, obesity, and bariatric surgery
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gastroenterology 130:1848-52. 2006
  3. ncbi Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55095, USA
    J Hepatol 41:943-9. 2004
    ..We aimed at determining the relation between leptin and liver fibrosis in human NAFLD...
  4. ncbi Current best treatment for non-alcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 4:611-23. 2003
    ..This article reviews the treatment modalities currently available for patients with NAFLD, including emerging data from clinical trials evaluating promising medications as well as possibilities for the future...
  5. ncbi Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 53:1716-20. 2008
    ..The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial...
  6. ncbi Nonalcoholic fatty liver disease and liver transplantation
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:523-34. 2006
    ..This paper reviews the prevalence of nonalcoholic fatty liver disease, its progressive potential, and the implications of this liver condition in both the pre- and post-liver transplantation setting...
  7. ncbi The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:846-54. 2007
    ..By applying this model, a liver biopsy would have been avoided in 549 (75%) of the 733 patients, with correct prediction in 496 (90%)...
  8. ncbi [Cholestatic syndromes]
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine
    Rev Gastroenterol Mex 70:45-51. 2005
  9. ncbi Nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Rev Gastroenterol Mex 70:52-6. 2005
    ..Current treatment relies on weight loss and exercise, although various insulin-sensitizing medications appear promising. Further research is needed to identify which patients will achieve the most benefit from therapy...
  10. ncbi Obesity and nonalcoholic fatty liver disease
    Paul Angulo
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Nutr Rev 65:S57-63. 2007
    ..Lifestyle intervention may improve NAFLD, but medications that increase insulin sensitivity and the antioxidant defenses in the liver deserve evaluation in carefully controlled trials...
  11. ncbi Nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    N Engl J Med 346:1221-31. 2002
  12. ncbi Treatment of nonalcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Hepatol 1:12-9. 2002
    ....
  13. ncbi Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:168-71. 2005
    ..Mycophenolate mofetil (MMF) is an immunosuppressive medication that inhibits T and B lymphocyte proliferation. The aim of this investigation was to determine the safety and estimated efficacy of MMF in patients with PBC...
  14. doi Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 55:476-83. 2010
    ..2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA...
  15. ncbi Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease
    Ariel E Feldstein
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 3:384-9. 2005
    ..Activated hepatic stellate cells (HSCs) are the source of collagen deposition in the liver. We aimed at determining whether an HSC activation score predicts fibrosis progression in NAFLD patients...
  16. ncbi The natural history of nonalcoholic fatty liver disease: a population-based cohort study
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 129:113-21. 2005
    ..The natural history of nonalcoholic fatty liver disease (NAFLD) in the community remains unknown. We sought to determine survival and liver-related morbidity among community-based NAFLD patients...
  17. pmc Nonalcoholic fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, Minn 55905, USA
    CMAJ 172:899-905. 2005
    ..In this article we discuss the etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management...
  18. ncbi Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
    Ayako Suzuki
    Gastroenterology and Hepat ology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    J Hepatol 43:1060-6. 2005
    ..The effects of lifestyle modifications in nonalcoholic fatty liver disease (NAFLD) are incompletely defined. We aimed at determining the association of changes in body weight and lifestyle with changes in serum ALT levels...
  19. doi The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Dig Dis Sci 57:1925-31. 2012
    ..The course of liver enzymes and their clinical correlations in nonalcoholic fatty liver disease (NAFLD) remains largely undescribed...
  20. ncbi Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 47:133-42. 2008
    ..001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38-2.36)...
  21. pmc Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease
    Michael Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 47:484-92. 2008
    ..The association between DHEA-S and severity of NAFLD persisted after adjusting for age. A relationship between disease/fibrosis severity and DHEA-S levels was not seen in patients with cholestatic liver diseases...
  22. ncbi Mycophenolate mofetil for the treatment of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 SW First Street, Rochester, MN 55905, USA
    Am J Gastroenterol 100:308-12. 2005
    ..In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC...
  23. ncbi Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia
    Ayako Suzuki
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:1912-9. 2007
    ....
  24. pmc The Framingham risk score and heart disease in nonalcoholic fatty liver disease
    Sombat Treeprasertsuk
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Liver Int 32:945-50. 2012
    ..The FRS accurately predicts the higher 10-year CHD risk in NAFLD patients, and helps identify those patients expected to derive the most benefit from early intervention to prevent CHD events...
  25. ncbi Primary sclerosing cholangitis in children: a long-term follow-up study
    Ariel E Feldstein
    Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 38:210-7. 2003
    ..In conclusion, PSC significantly decreases survival in this child population. Although pharmacologic therapy may improve symptoms and liver test results initially, it does not seem to impact the long-term outcome...
  26. ncbi Chronological development of elevated aminotransferases in a nonalcoholic population
    Ayako Suzuki
    Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 41:64-71. 2005
    ..In conclusion, this cohort study clearly showed chronological ordering and an association between development of elevated aminotransferases and risk factors of NAFLD...
  27. ncbi The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 42:132-8. 2005
    ..The histological course of nonalcoholic fatty liver disease (NAFLD) remains undescribed. Therefore, we examined the liver histology of NAFLD patients who had undergone sequential liver biopsies...
  28. ncbi Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 42:762-71. 2005
    ..Although in this study oral alendronate appears to be well tolerated in patients with PBC, larger studies are needed to formally evaluate safety...
  29. pmc Utility of a new model to diagnose an alcohol basis for steatohepatitis
    Winston Dunn
    Advanced Liver Disease Study Group and Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 131:1057-63. 2006
    ..Thus, the aim of our study was to create and validate a model to diagnose ALD in patients with steatohepatitis...
  30. ncbi Abnormal hepatic biochemistries in patients with inflammatory bowel disease
    Flavia D Mendes
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:344-50. 2007
    ..We determined the prevalence of abnormal hepatic biochemistries and chronic liver disease in a cohort of IBD patients, and we compared patients with normal and abnormal liver biochemistries...
  31. pmc Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease
    Flavia D Mendes
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 10:1028-33.e2. 2012
    ..Little is known about the prevalence and severity of portal hypertension in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the prevalence and noninvasive predictors of portal hypertension in patients with NAFLD...
  32. ncbi Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis
    Ayako Suzuki
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 5:259-64. 2007
    ..Optimal selection of PBC patients for HCC screening needs to be determined for effective screening. In this study, we aimed to explore clinical predictors of HCC in PBC patients...
  33. ncbi Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study
    Cynthia Levy
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Liver Int 25:117-21. 2005
    ..Bone disease is common in patients with primary biliary cirrhosis (PBC). Our aim was to evaluate safety and efficacy of raloxifene in this population...
  34. ncbi Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Int 27:220-6. 2007
    ....
  35. ncbi Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:1244-50. 2007
    ..Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC...
  36. ncbi Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic W19A, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:770-8. 2004
    ..In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH...
  37. ncbi Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?
    Ahmad S Abdulkarim
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Hepatol 40:380-4. 2004
    ..Both an infectious etiology and molecular mimicry have been implicated. The aim is to study the prevalence of Chlamydial antigens and RNA in the liver tissue of patients with PBC...
  38. doi Varices in early histological stage primary biliary cirrhosis
    Ahmad H Ali
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 45:e66-71. 2011
    ..We sought to determine the prevalence, clinical characteristics, and predictors of EV in early-stage PBC, as well as to evaluate the effectiveness of recent guidelines regarding EV screening in PBC patients...
  39. ncbi A pilot trial of pentoxifylline in nonalcoholic steatohepatitis
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:2365-8. 2004
    ..Pentoxifylline inhibits TNF alpha production. We therefore conducted a 12-month pilot trial to assess the efficacy and safety of pentoxifylline (1,600 mg/day) among 20 patients with NASH...
  40. ncbi The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis
    Leon A Adams
    Department of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MI, USA
    Liver Int 26:298-304. 2006
    ..We sought to examine whether the metabolic syndrome, hepatic steatosis or steatohepatitis influenced hepatic fibrosis among patients with HH and iron overload...
  41. ncbi Hepatitis C and steatosis
    Einar Bjornsson
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arch Med Res 38:621-7. 2007
    ..However, further studies are necessary to determine whether weight reduction improves response to antiviral therapy...
  42. ncbi The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:1316-20. 2004
    ..We aimed at examining the prevalence of autoantibodies and autoimmune hepatitis among patients with NAFLD...
  43. ncbi Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease
    Ayako Suzuki
    Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Liver Int 25:779-86. 2005
    ..To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)...
  44. ncbi When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 1:89-95. 2003
    ..This study was undertaken to determine which variables indicate the need for liver biopsy in patients with positive AMA and suspected PBC...
  45. ncbi Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Hepatology 39:909-14. 2004
    ..The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease...
  46. ncbi Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis
    Joanna L Siegel
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    J Clin Gastroenterol 37:183-5. 2003
    ..Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug...
  47. ncbi Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis
    Andrea A Gossard
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1330-3. 2005
    ..We also compared the natural history of patients diagnosed with SSC to a cohort with a diagnosis of primary sclerosing cholangitis (PSC)...
  48. ncbi Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis
    Claudia O Zein
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, MN, USA
    Hepatology 39:204-10. 2004
    ..Our results suggest a clinically applicable and useful approach to identify patients with PSC who are more likely to benefit from endoscopic screening for esophageal varices...
  49. ncbi Results of long-term ursodiol treatment for patients with primary biliary cirrhosis
    Roberta Jorgensen
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:2647-50. 2002
    ..To address this, we reviewed the long-term results from patients enrolled in our original randomized study with up to 12 yr of follow-up...
  50. ncbi Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis
    Einar Bjornsson
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:1677-82. 2007
    ..We aimed at characterizing the clinical presentation and prognosis of cholangiocarcinoma in youth with and without primary sclerosing cholangitis (PSC)...
  51. ncbi Non-alcoholic fatty liver disease
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    J Gastroenterol Hepatol 17:S186-90. 2002
    ..Liver transplantation is a life-extending therapeutic alternative for patients with end-stage NAFLD, but NAFLD may recur after liver transplantation...
  52. ncbi Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis
    K V Narayanan Menon
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905 0001, USA
    Am J Gastroenterol 98:889-92. 2003
    ..The aim of the present study was to determine the safety as well as the efficacy of estrogen replacement therapy with respect to bone mass in postmenopausal women with primary biliary cirrhosis...
  53. ncbi Small-duct primary sclerosing cholangitis: a long-term follow-up study
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hepatology 35:1494-500. 2002
    ..Some patients, however, progress to classic PSC and/or end-stage liver disease with the consequent necessity of liver transplantation...
  54. ncbi [Fatty liver and steatotic non-alcoholic hepatitis]
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, Rochester, Minnesota, USA
    Rev Gastroenterol Mex 69:140-8. 2004
  55. ncbi Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:1191-7. 2002
    ..Our specific aim was to evaluate the revised IAHG scoring system and its ability to identify AIH overlap in PBC...
  56. ncbi Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis
    Kelly Burak
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:523-6. 2004
    ..5 yr, which is dramatically higher than the rates in the general population. Variceal bleeding is a major risk factor for the later development of CCA...
  57. ncbi Pirfenidone in the treatment of primary sclerosing cholangitis
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota P 55905, USA
    Dig Dis Sci 47:157-61. 2002
    ..Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC...
  58. ncbi Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
    Ariel E Feldstein
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905 USA
    Gastroenterology 125:437-43. 2003
    ..Thus, the aims of this study were to quantify hepatocyte apoptosis in NASH, correlate it with disease severity, and identify possible mechanisms of apoptosis induction...
  59. ncbi Recurrent idiopathic hepatitis: a new entity?
    Jason R Phillips
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Gastroenterol 37:267-9. 2003
    ..Our goals were to describe a new clinical entity, which we termed recurrent idiopathic hepatitis. We provide a case report of this entity and conclude that this is perhaps a new entity somewhat analogous to recurrent idiopathic cholestasis...
  60. ncbi Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 40:39-45. 2004
    ..30 US dollars would be required. In conclusion, MRC has comparable accuracy to ERCP and results in cost savings when used as the initial test strategy for diagnosing PSC...
  61. ncbi Treatment of non-alcoholic steatohepatitis
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Gastroenterol 16:797-810. 2002
    ....
  62. ncbi Is there a role for liver biopsy in primary sclerosing cholangitis?
    Kelly W Burak
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:1155-8. 2003
    ..The purpose of this study was to examine how often routine liver biopsies provide important information in patients with PSC...
  63. pmc Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis
    Ayako Suzuki
    Division of Gastroenterology and Hepatology, Mayo Clinic, W19A, 200 First Street, SW, Rochester, MN 55905, USA
    Dev Immunol 9:55-61. 2002
    ..However, the data, which limited in scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing evidence of tolerance induction in autoimmunity...
  64. ncbi [Auto-antibodies in liver disease]
    Aldo J Montano Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, 200 First Street S W, Rochester, Minnesota 55905, USA
    Rev Gastroenterol Mex 72:62-8. 2007
    ..Recognition and characterization of new autoantibodies is expected to improve the diagnostic precision, provide diagnostic parameters, and elucidate target autoantigens for the management of liver diseases...
  65. ncbi Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy
    Leon A Adams
    Am J Gastroenterol 98:2348-50. 2003
  66. ncbi Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis
    Cynthia Levy
    Am J Gastroenterol 99:269-70. 2004
  67. doi Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial
    Valerio Nobili
    Liver Unit, Bambino Gesu Children s Hospital and Research Institute, Rome, Italy
    Hepatology 48:119-28. 2008
    ..The improvement in all these parameters was not significantly different between the two groups...
  68. doi The natural history of small-duct primary sclerosing cholangitis
    Einar Bjornsson
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Gastroenterology 134:975-80. 2008
    ..We aimed at determining the natural history and long-term outcomes of a large number of patients with small-duct PSC...
  69. ncbi Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Leon A Adams
    Clin Gastroenterol Hepatol 2:1059-60. 2004
  70. ncbi The bulge, booze, and the liver
    Leon A Adams
    Clin Gastroenterol Hepatol 3:1195-7. 2005
  71. ncbi Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis
    Manuela Neuman
    Division of Clinical Pharmacology, Sunnybrook and Women s Health Sciences Center, University of Toronto, Toronto, Ontario, Canada
    J Gastroenterol Hepatol 17:196-202. 2002
    ..Our aims were to determine: (i) the relationship between serum levels of TNF-alpha and TGF-beta and the severity of PBC; and (ii) the effects of UDCA therapy on TNF-alpha and TGF-beta levels in patients with PBC...
  72. ncbi NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice
    Valerio Nobili
    Liver Unit, Bambino Gesu Children s Hospital, Rome, Italy
    Hepatology 44:458-65. 2006
    ..Obesity and older age are independently associated with increased liver fibrosis. A simple lifestyle advice program significantly improves insulin resistance, and the liver disease in pediatric NAFLD...
  73. ncbi Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis
    Ayako Suzuki
    Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Liver Int 26:1209-16. 2006
    ..In this study, we assessed diagnostic accuracy of serum aminotransferase changes in predicting histological changes in NASH trials...
  74. ncbi Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease
    Leon A Adams
    School of Medicine and Pharmacology, The University of Western Australia, Liver Transplant Unit, Sir Charles Gairdner Hospital, Nedlands, Australia
    Clin Liver Dis 11:25-35, viii. 2007
    ....

Research Grants1

  1. Prognosis of Nonalcoholic Fatty Liver Disease
    Paul Angulo; Fiscal Year: 2009
    ....